ROSEN Recognized Investor Counsel Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTGN
Rosen Law Firm Alerts Vistagen Therapeutics (VTGN) Investors of Securities Class Action and Approaching Deadline
On January 25, 2026, Rosen Law Firm — a globally recognized investor rights law firm — issued a statement urging individuals who purchased the common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) during a defined class period to secure legal counsel before a critical deadline in an ongoing securities class action lawsuit.
Overview of the Securities Class Action
The Rosen Law Firm announced that it has commenced a class action lawsuit on behalf of purchasers of Vistagen Therapeutics common stock acquired between April 1, 2024 and December 16, 2025 (the “Class Period”). This lawsuit seeks to hold accountable those alleged to have issued materially misleading information that affected the company’s stock price during this time.
Investors who fall within this category may be eligible to seek compensation for financial losses without paying any out-of-pocket fees or costs, as Rosen Law Firm operates on a contingency fee basis.
Important Deadline: March 16, 2026
Investors who wish to participate in the case and potentially serve as the lead plaintiff must file a motion with the court no later than March 16, 2026. The lead plaintiff plays a key role in representing the entire class in directing the litigation and working with counsel.
To join the lawsuit, interested parties can submit their information through the Rosen Law Firm’s case portal or contact the firm directly for more details.
Allegations in the Lawsuit
According to the complaint, the defendants are said to have provided investors with materially positive information regarding Vistagen’s development plans — especially related to the investigational drug fasedienol, under study for acute treatment of social anxiety disorder (SAD). These statements highlighted expected success in clinical trials such as PALISADE-2 and enhancements to the PALISADE-3 trial.
However, the lawsuit alleges that while disseminating these optimistic projections, the defendants also concealed adverse facts about the Phase 3 PALISADE-3 trial, effectively misleading the investing public. When true information came to light, the stock price allegedly suffered, resulting in investor losses.
Why Secure Counsel Early?
The Rosen Law Firm emphasizes the importance of selecting experienced legal counsel. The notice warns that many firms issuing similar alerts lack meaningful experience in securities litigation or act merely as intermediaries, referring clients to other firms. Investors are encouraged to choose counsel with a proven track record in leadership roles in securities class actions.
Rosen Law Firm highlights its own history of investor recovery achievements, including notable settlements and recognition within the legal community.
Next Steps for Investors
Investors wishing to learn more about the class action or to join the lawsuit should visit the case submission page provided by Rosen Law Firm, call their toll-free information line, or email their legal team for assistance.
It’s important to note that no class has yet been certified in this action. Until certification, individuals are not legally represented unless they retain counsel themselves. Remaining a passive class member is an option, but this may limit an investor’s role in the litigation process.
Contact Information for Rosen Law Firm
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Email: [email protected]
Website: www.rosenlegal.com